SCB-1019 is under clinical development by Clover Biopharmaceuticals and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase I drugs for Respiratory Syncytial Virus (RSV) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SCB-1019 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SCB-1019 is under development for the prevention of respiratory syncytial virus infection. Vaccine consists of trimerized RSV fusion glycoprotein, which is being developed based on Trimer-Tag technology. SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B).
Clover Biopharmaceuticals overview
Clover Biopharmaceuticals (Clover) is a biotechnology company that focuses on discovering, developing and commercializing biologic therapies. The company’s pipeline products include SCB-2019 (CpG 1018/Alum), SCB-2020S (CAS-1), Bivalent COVID-19 Vaccine (SCB-2019 + SCB-2022B), Rabies Vaccine, RSV Vaccine, Influenza Vaccine, SCB-313, SCB-219M. It utilizes its proprietary technology platform Trimer-Tag to develop vaccines for rabies, influenza, respiratory syncytial virus (RSV) and human immunodeficiency virus (HIV). The company also carries out research and development on therapies for oncology and autoimmune diseases. Clover is headquartered in Shanghai, China.
For a complete picture of SCB-1019’s drug-specific PTSR and LoA scores, buy the report here.